New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline

References

• Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016 Feb 18;150:1393-1407.e5.
   Web of Science ®Google Scholar
• Cremonini F1, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am. 2005 Jun;34(2):189–204.
   PubMed Web of Science ®Google Scholar
• Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014 Nov;40(9):1023–1034.
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol. 2003 Mar;98(3):600–607.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775–85.
   PubMed Web of Science ®Google Scholar
• Palsson OS, Baggish J, Whitehead WE. Episodic nature of symptoms in irritable bowel syndrome. Am J Gastroenterol. 2014 Sep;109(9):1450–1460.
   PubMed Web of Science ®Google Scholar
• Su A, Shih W, Presson AP, et al. Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. Neurogastroenterol Motil. 2014;26(1):36–45.
   PubMed Web of Science ®Google Scholar
• Hellström PM, Saito YA, Bytzer P, et al. Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria. Am J Gastroenterol. 2011;106(7):1299–1307.
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Lacy BE, et al., Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014 Aug;109(Suppl 1):S2–26.
   PubMed Web of Science ®Google Scholar
• Zheng L, Lai Y, Lu W, et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial. Clin Gastroenterol Hepatol. 2015 Jul;13(7):1285–1292.
   PubMed Web of Science ®Google Scholar
• Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome–a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987;130:77–80.
   PubMedGoogle Scholar
• Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014 Sep;109(9):1350–1365.
   PubMed Web of Science ®Google Scholar
• Aziz I, Kurien M, Sanders DS, et al. Screening for bile acid diarrhoea in suspected irritable bowel syndrome. Gut. 2015 May;64(5):851.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Acosta A, Busciglio I, et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2015 Mar;41(5):438–448.
   PubMed Web of Science ®Google Scholar
• Bajor A, Törnblom H, Rudling M, et al. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut. 2015 Jan;64(1):84–92.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000 Mar 25;355(9209):1035–1040.
   PubMed Web of Science ®Google Scholar
• Tong K, Nicandro JP, Shringarpure R, et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol. 2013 Sep;6(5):344–357.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Krause R, Deveze S, et al. Evaluation of alosetron using the new FDA composite endpoint demonstrates strong treatment effect in females with severe irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2014;109(Suppl 2):S535.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Ida M, Akiho H, et al. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014 Jun;12(6):953–959.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150(2):358-366.e8
   Web of Science ®Google Scholar
• Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014 Oct;63(10):1617–1625.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, et al., TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22–32.
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov NCT01543178.
   Google Scholar
• Cash BD, Lacy BE, Rao T, et al. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Expert Opin Pharmacother. 2015;8:1–12.
   Web of Science ®Google Scholar
• Garnock-Jones KP. Eluxadoline: first global approval. Drugs. 2015 Jul;75(11):1305–1310.
   PubMed Web of Science ®Google Scholar
• Wade PR, Palmer JM, McKenney S, et al. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/µ opioid receptor antagonist. Br J Pharmacol. 2012 Nov;167(5):1111–1125.
   PubMed Web of Science ®Google Scholar
• Breslin HJ, Diamond CJ, Kavash RW, et al. Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant irritable bowel syndrome (IBS-d). Bioorg Med Chem Lett. 2012 Jul 15;22(14):4869–4872.
   PubMed Web of Science ®Google Scholar
• Fujita W, Gomes I, Dove LS, et al. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol. 2014 Dec 1;92(3):448–456.
   PubMed Web of Science ®Google Scholar
• Actavis. ViberziTM (eluxadoline tablets): US prescribing information 2015. [ cited 2015 Jun 15]. Available from: http://www.actavis.com
   Google Scholar
• Davenport JM, Covington P, Bonifacio L, et al. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol. 2015;55(5):534–542.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration. Department of justice schedules of controlled substances: placement of eluxadoline into schedule IV. Final Rule Fed Regist. 2015 Nov 12;80(218):69861–69864.
   PubMedGoogle Scholar
• Levy-Cooperman N, McIntyre G, Bonifacio L, et al. Abuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist. J Pharmacol Exp Ther. 2016 Dec;359(3):471–481.
   PubMed Web of Science ®Google Scholar
• Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013 Aug;145(2):329–338.
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374(3):242–253.
   PubMed Web of Science ®Google Scholar
• Atarodi SRS, Whorwell PJ. Faecal incontinence - the hidden scourge of irritable syndrome: a cross sectional study. BMJ Open Gastroenterology. 2014;1:1–6.
   Google Scholar
• Dekel R, Drossman DA, Sperber AD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs. 2013 Mar;22(3):329–339.
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health related quality of life. Gastroenterology. 2000;119:654–660.
   PubMed Web of Science ®Google Scholar
• Miller V, Hopkins VL, Whorwell PJ. Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2:1064–1068.
   PubMed Web of Science ®Google Scholar
• Coffin B, Follet M, Mackinnon J, et al. The burden of moderate-to-severe irritable bowel syndrome with constipation (Ibs-C) in France: a comparison with the European results from the ibis-c observational study. Value Health. 2015 Nov;18(7):A632.
   PubMed Web of Science ®Google Scholar
• Layer P, Andresen V, Diemert S, et al. Economic burden and quality of life of moderate-to-severe irritable bowel syndrome with constipation (Ibs-C) in Germany: results from the Ibis-C study. Value Health. 2015 Nov;18(7):A624.
   PubMed Web of Science ®Google Scholar
• Canavan C, West J, Card T. Calculating total health service utilisation and costs from routinely collected electronic health records using the example of patients with irritable bowel syndrome before and after their first gastroenterology appointment. Pharmacoeconomics. 2016 Feb;34(2):181–194.
   PubMed Web of Science ®Google Scholar
• Buono JL, Tourkodimitris S, Sarocco P, et al. Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. Am Health Drug Benefit. 2014;7(5):289–297.
   PubMedGoogle Scholar
• Tack J, Schumacher K, Tonini G, et al., the Iris-2 investigators. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut. 2016 Apr 15:pii: gutjnl-2015-310683. DOI:10.1136/gutjnl-2015-310683
   Google Scholar
• www. clinicaltrials.gov NCT02120027.
   Google Scholar
• Wouters MM, Balemans D, Van Wanrooy S, et al. Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016 Apr;150(4):875–87.e9. DOI:10.1053/j.gastro.2015.12.034
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov NCT01908465.
   Google Scholar